Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96AD5

UPID:
PLPL2_HUMAN

ALTERNATIVE NAMES:
Adipose triglyceride lipase; Calcium-independent phospholipase A2-zeta; Desnutrin; Pigment epithelium-derived factor receptor; TTS2.2; Transport-secretion protein 2

ALTERNATIVE UPACC:
Q96AD5; O60643; Q5EFF5; Q6XYE5; Q96ET6; Q9NQ61; Q9NQ62

BACKGROUND:
Known by several names including Desnutrin and Adipose triglyceride lipase, this enzyme is crucial for breaking down triglycerides into free fatty acids, a process essential for energy balance and lipid storage management. Its activities extend to regulating adiposome size and participating in the lipolytic cascade, underscoring its importance in lipid metabolism.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Patatin-like phospholipase domain-containing protein 2 could open doors to potential therapeutic strategies for managing Neutral lipid storage disease with myopathy. This disease's link to the protein offers a promising avenue for developing targeted therapies that address the underlying mechanisms of lipid accumulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.